Drugs for Lung Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 163)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Carboplatin |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
41575-94-4 |
10339178
498142
38904
|
|
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
azanide
Blastocarb
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
Carbopaltin
Carboplat
carboplatin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Carbosin
Carbotec
Cbdca
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
Cyclobutane-1,1-dicarboxylate
cyclobutane-1,1-dicarboxylic acid
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
|
EINECS 255-446-0
Ercar
EU-0100230
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
IUPAC: Azane
JM 8
JM8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
Lopac0_000230
Lopac-C-2538
LS-117689
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
Nealorin
Neocarbo
NINDS_000892
NSC 201345
NSC 241240
NSC201345
NSC241240
NSC-241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
platinum(2+)
Platinum(II), (1, 1-cyclobutanedicar
Platinum, {diammine[1,1-cyclobut
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Ribocarbo
S1215_Selleck
SPBio_000716
Spectrum_001529
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
UNII-BG3F62OND5
|
|
| 2 |
|
Cisplatin |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
15663-27-1 |
84093
441203
2767
|
|
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
CHEBI:35852
CID441203
Cis Pt II
cis-[PtCl2(NH3)2]
cis-DDP
Cis-DDP
Cis-Diaminedichloroplatinum
cis-diamminedichloridoplatinum(II)
cis-Diamminedichloroplatinum
Cis-Diamminedichloroplatinum
cis-diamminedichloroplatinum(II)
cis-Dichlorodiammineplatinum(II)
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
CPD0-1392
CPDC
|
CPDD
DB00515
DDP
DDPT
Diamminedichloroplatinum
EU-0100918
Lederplatin
nchembio773-comp1
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-DDP
Trans-Diaminedichloroplatinum
trans-diamminedichloridoplatinum(II)
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
| 3 |
|
Docetaxel |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
114977-28-5 |
148124
|
|
Synonyms:
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
01885_FLUKA
114977-28-5
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC1L3WHJ
AC-383
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
docetaxel
Docetaxel
Docetaxel (INN)
docetaxel 114977-28-5
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxel, Trihydrate
Docetaxol
|
EmDOC
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
Taxoltere metro
Taxotere
Taxotere (TN)
Taxotere(R)
TXL
XRP-6976L
|
|
| 4 |
|
Gefitinib |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
184475-35-2 |
123631
|
|
Synonyms:
184475-35-2
4-(3'-chloro-4'-fluoroanilino)-7-Methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
gefitinib
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
Gelfitinib
HMS2089B19
I01-1227
|
IRE
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
nchembio.117-comp18
nchembio866-comp14
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZINC19632614
|
|
| 5 |
|
Pemetrexed |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
150399-23-8, 137281-23-3 |
446556
60843
|
|
Synonyms:
(2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
(2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
137281-23-3
150399-23-8
1juj
2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID
AC1L1U1D
AC1L2PDW
AC1L98DY
AC1L9JT6
AC1OCF51
AC1Q5R1W
Alimta
ALIMTA
Alimta (TN)
Bio-0078
C20H19N5O6.2Na
C20H21N5O6
CHEBI:195145
CHEBI:43746
CHEBI:474008
CHEMBL1200373
CHEMBL225072
CHEMBL59843
CID125891
CID394493
CID446556
CID60843
CID6918197
D03828
D07472
DB00642
disodium (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
disodium (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
Disodium N-(p-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-L-glutamate
|
Disodium, pemetrexed
HSDB 7316
I06-1253
I06-1294
I06-2128
L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-, disodium salt
LS-172988
LS-173384
LY 231,514
LY 231514
LY-231,514
LY-2315
LY231514
LY-231514
LY231514 disodium
LYA
MTA
N-(4-(2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-D)Pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
n-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid
NCGC00167517-01
nchembio.108-comp6
NCI60_035021
NSC698037
Pemetrexed
Pemetrexed (INN)
Pemetrexed [INN:BAN]
Pemetrexed disodium
Pemetrexed Disodium
Pemetrexed disodium (USAN)
Pemetrexed disodium [USAN]
Rolazar
ST51053024
Tifolar
UNII-04Q9AIZ7NO
UNII-2PKU919BA9
|
|
| 6 |
|
Nedaplatin |
Approved, Investigational |
Phase 4,Phase 3 |
|
95734-82-0 |
|
|
Synonyms:
(glycolato-O,O')diammineplatinum(II)
CDGP
cis-Diammine (glycolato)platinum
|
cis-diammine(glycolato)platinum
cis-Diammine(glycolato)platinum(II)
|
|
| 7 |
|
Gemcitabine |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
95058-81-4 |
60750
|
|
Synonyms:
103882-84-4
122111-03-9
2',2'-DFDC
2',2'-DiF-dC
2',2'-difluoro-2'-Deoxycytidine
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-Hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFdC
DFDC
DFdCyd
Folfugem
Gamcitabine
Gemcel
Gemcin
Gemcitabin
|
Gemcitabina
Gemcitabina [INN-Spanish]
gemcitabine
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
GemLip
Gemtro
Gemzar
Gemzar (hydrochloride)
GEO
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY188011
LY-188011
NCGC00168784-01
NChemBio.2007.10-comp25
nchembio.573-comp7
nchembio.90-comp2
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
Zefei
ZINC18279854
|
|
| 8 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
33069-62-4 |
36314
|
|
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-epi-Paclitaxel
7-Epipaclitaxel
7-Epi-paclitaxel
7-epi-Taxol
7-Epitaxol
7-Epi-taxol
AB00513812
ABI 007
abi-007
ABI007
ABI-007
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
AC1L1IOG
AC1L1VJI
AC1L9AVF
AC-675
ACon1_002231
albumin-bound paclitaxel
Ambotz33069-62-4
ANX-513
Anzatax
Asotax
BIDD:PXR0046
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
Bris taxol
Bristaxol
BSPBio_000290
BSPBio_001152
BSPBio_002614
C07394
C466458
C47H51NO14
Capxol
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
cMAP_000068
CPD-8718
D00491
DB01229
DHP-107
DHP-208
DivK1c_000441
DRG-0190
DTS-301
Ebetaxel
EmPAC
Epitaxol
EU-0101201
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
|
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LipoPac
LMPR0104390001
Lopac0_001201
LS-31070
MBT 0206
MEGxp0_001940
Micellar Paclitaxel
Mitotax
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
MPI-5018
nab-paclitaxel
Nanotaxel
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
NCI60_000601
Neuro_000060
NINDS_000441
NK 105
Nova-12005
NP-010981
NSC 125973
NSC125973
NSC-125973
NSC358882
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
paclitaxel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S1150_Selleck
S-8184 Paclitaxel Injectable Emulsion
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
Spectrum_001536
SPECTRUM1503908
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
ST50306996
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TaxAlbin
Taxol
TAXOL
TAXOL (TN)
Taxol a
Taxol A
Taxol Konzentrat
TAXOL, 10-EPI,
Taxol, bris
Taxol.RTM. (Registered Trademark)
TXL
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
weekly paclitaxel
Xorane
Yewtaxan
|
|
| 9 |
|
Folic Acid |
Approved, Nutraceutical, Vet_approved |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
59-30-3 |
6037
|
|
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
AI3-26387
AKOS000503224
Antianemia factor
Apo-Folic
ARONIS014410
b9, Vitamin
BIDD:ER0563
BIDD:GT0641
BIF0608
bmse000299
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat b activ
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
Facid
Factor U
FOL
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
folic acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
|
Folina (Italy)
Folipac
Folsaeure
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
Incafolic
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
Liver lactobacillus casei factor
Liver Lactobacillus casei factor
LS-2157
Millafol
Mission prenatal
Mittafol
MLS001304016
MLS001335861
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-Pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
nchembio.108-comp10
Nifolin
Nifolin [Denmark]
NINDS_000494
Novofolacid
Novofolacid [Canada]
N-Pteroyl-L-glutamate
N-Pteroyl-L-glutamic acid
NSC 3073
PGA
PGA (VAN)
Prestwick_230
Prestwick3_000627
PteGlu
Pteroylglutamate
Pteroylglutamic acid
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
Serum Folate Level
SMP2_000137
SMR000471860
SPBio_001357
Spectrum_001381
SPECTRUM1502020
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin b9
Vitamin B9
Vitamin Bc
Vitamin BC
Vitamin be
Vitamin Be
Vitamin m
Vitamin M
|
|
| 10 |
|
leucovorin |
Approved, Nutraceutical |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
58-05-9 |
143
6006
|
|
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-formyltetrahydrofolic acid
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
Acid, folinic
Acide folinique
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
Citrovorum factor
Factor, citrovorum
folinate
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
|
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monosodium salt
Leucovorinum
Leukovorin
Leukovorum
Levoleucovorin
L-leucovorin
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Rescuvolin
Welcovorin
Wellcovorin
|
|
| 11 |
|
Antimitotic Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 12 |
|
Erlotinib Hydrochloride |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
183319-69-9 |
176871
|
|
Synonyms:
|
| 13 |
|
Folic Acid Antagonists |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 14 |
|
Nucleic Acid Synthesis Inhibitors |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 15 |
|
Protein Kinase Inhibitors |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 16 |
|
Vitamin B Complex |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 17 |
|
Albumin-Bound Paclitaxel |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 18 |
|
Anti-Infective Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 19 |
|
Antimetabolites |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 20 |
|
Antimetabolites, Antineoplastic |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 21 |
|
Antineoplastic Agents, Phytogenic |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 22 |
|
Antiviral Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 23 |
|
Immunosuppressive Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 24 |
|
Folate |
Nutraceutical |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 25 |
|
tyrosine |
Nutraceutical |
Phase 4,Phase 2,Phase 1 |
|
|
|
| 26 |
|
Vitamin B9 |
Nutraceutical |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 27 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 3,Phase 1 |
|
50-18-0, 6055-19-2 |
2907
|
|
Synonyms:
(-)-Cyclophosphamide
(+-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
ASTA B518
B 518
B-518
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
BRN 0011744
BSPBio_002099
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
CID2907
Clafen
Claphene
CP
CPA
CTX
CY
Cycloblastin
Cyclophosphamid
cyclophosphamide
Cyclophosphamide
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (+-)-Isomer
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
|
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
DivK1c_000246
EINECS 200-015-4
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
EU-0100238
Genoxal
Hexadrin
HMS2090A12
HSDB 3047
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
Ledoxina
Lopac0_000238
Lopac-C-0768
LS-1302
LS-99787
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI60_002097
NCI-C04900
Neosar
NINDS_000246
NSC 26271
NSC26271
NSC-26271
NSC273033
NSC273034
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra waste number U058
Rcra Waste Number U058
Revimmune
S1217_Selleck
Semdoxan
Sendoxan
Senduxan
SK 20501
SPBio_001071
Spectrum_000858
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
STK177249
STOCK2S-91217
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
|
|
| 28 |
|
Etoposide |
Approved |
Phase 3,Phase 2,Phase 1 |
|
33419-42-0 |
36462
|
|
Synonyms:
(−)-etoposide
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4-Demethylepipodophyllotoxin b-D-ethylideneglucoside
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4-demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
alpha-D-Glucopyranosyl isomer etoposide
Ambap33419-42-0
Baxter brand OF etoposide
Baxter oncology brand OF etoposide
Bio1_000489
Bio1_000978
Bio1_001467
BPBio1_000673
BRD-K37798499-001-02-5
Bristol myers brand OF etoposide
Bristol myers squibb brand OF etoposide
Bristol-myers brand OF etoposide
Bristol-myers squibb brand OF etoposide
BSPBio_000611
C01576
CCRIS 2392
Celltop
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl epipodophyllotoxin ethylidine glucoside
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
eto GRY
eto-GRY
Etomedac
ETOP
Etopol
Etopophos
Etopophos (phosphate salt)
Etopos
|
etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposide pierre fabre
Etoposide teva
Etoposide, (5a alpha)-isomer
Etoposide, (5a alpha,9 alpha)-isomer
Etoposide, (5S)-isomer
Etoposide, alpha D glucopyranosyl isomer
Etoposide, alpha-D-glucopyranosyl isomer
Etoposido
Etoposido [INN-Spanish]
etoposido Ferrer farma
Etoposidum
Etoposidum [INN-Latin]
Etosid
Exitop
Ferrer brand OF etoposide
Gry brand OF etoposide
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
Lastet
Lemery brand OF etoposide
LS-1214
Medac brand OF etoposide
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
nchembio.573-comp8
nchembio873-comp2
NK 171
Novartis brand OF etoposide
NSC 141540
NSC141540
NSC-141540
Onkoposid
Onkoworks brand OF etoposide
Pharmachemie brand OF etoposide
Pierre fabre brand OF etoposide
Prasfarma brand OF etoposide
Prestwick_211
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Riboposid
Ribosepharm brand OF etoposide
S1225_Selleck
SAM001246880
Sanfer brand OF etoposide
SMR000112002
SPBio_002532
ST056353
Tedec meiji brand OF etoposide
Teva brand OF etoposide
Toposar
trans-Etoposide
UNII-6PLQ3CP4P3
Vepesid
VePesid
VePESID (TN)
Vepesid J
Vepeside
Vépéside sandoz
Vépéside-sandoz
VP 16
VP 16 (pharmaceutical)
VP 16213
VP 16-213
VP-16
VP-16-213
ZINC03830818
ZINC03938684
Zuyeyidal
|
|
| 29 |
|
Vinorelbine |
Approved, Investigational |
Phase 3,Phase 2,Phase 1 |
|
71486-22-1 |
60780
44424639
|
|
Synonyms:
5'-Noranhydrovinblastine
5'-Nor-anhydrovinblastine
71486-22-1
AC1L1KVK
AC1L1TWQ
AC1L75Q4
Ambap71486-22-1
ANX-530
BIDD:PXR0186
C45H54N4O8
CHEBI:480999
CHEMBL607994
CID355119
CID5311497
CID5672
CID60780
CID6426842
D08680
DB00361
Eunades
Exelbine
HMS2090E13
HSDB 7665
I06-0084
I06-0085
KW 2307
KW 2307 base
KW-2307
LS-97533
methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
|
methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
MolPort-006-822-661
MolPort-006-823-869
Navelbine
Navelbine (TN)
Navelbine base
Navelbine Base
NCGC00165966-02
Nor-5'-anhydrovinblastine
NVB
SDP-012
UNII-Q6C979R91Y
Vinorelbin
Vinorelbina
Vinorelbina [Spanish]
vinorelbine
Vinorelbine
Vinorelbine (INN)
Vinorelbine [INN:BAN]
Vinorelbine bitartrate
Vinorelbine Bitartrate
Vinorelbine ditartarate
Vinorelbine Ditartarate
Vinorelbine ditartrate
Vinorelbine Ditartrate
Vinorelbine tartrate
Vinorelbine Tartrate
Vinorelbinum
Vinorelbinum [Latin]
|
|
| 30 |
|
Vinblastine |
Approved |
Phase 3,Phase 2,Phase 1 |
|
865-21-4 |
13342
241903
|
|
Synonyms:
(2a,2'b,3b,4a,5b)-VINCALEUKOBLASTINE
(2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE
(2xi,3beta,4'beta,19xi)-vincaleukoblastine
(2α,2'β,3β,4α,5β)-vincaleukoblastine
(3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-methyl 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino(8,1-cd)carbazole-5-carboxylate
143-67-9
1z2b
29060-LE
865-21-4
AC1L21JC
AC1L68D2
AC1MXZJ2
AC-20335
BIDD:PXR0201
Bio-0111
BRD-K01188359-065-02-5
BSPBio_001228
BSPBio_003594
C07201
C46H58N4O9
CCRIS 9002
Cell pharm brand OF vinblastine sulfate
Cellblastin
CHEBI:171516
CHEBI:27375
CHEMBL159
CHEMBL607706
CID13342
CID241903
CID3823887
CID6710780
D08675
DB00570
EG labo brand OF vinblastine sulfate
EINECS 212-734-0
Faulding brand OF vinblastine sulfate
Gastrozepin brand OF vinblastine sulfate
Gry brand OF vinblastine sulfate
Hexal brand OF vinblastine sulfate
HMS2090K05
HSDB 3263
KBio3_003033
Lemblastine
Lemery brand OF vinblastine sulfate
Lilly brand OF vinblastine sulfate
|
LS-1859
LS-187263
MolPort-002-518-262
MolPort-005-910-359
NCGC00022585-04
NCGC00181127-01
NChemBio.2007.10-comp22
nchembio873-comp22
NCI60_004200
NCI-C04842
NDC 0002-1452-01
Neuro_000020
Nincaluicolflastine
NSC 47842
Rozevin
SPBio_000680
Spectrum2_000890
Spectrum3_001994
STOCK1N-38480
Sulfate, vinblastine
UNII-5V9KLZ54CY
Velban
Velbe
Vinblastin
Vinblastin hexal
Vinblastina
Vinblastina (TN)
Vinblastina [Dcit]
Vinblastina [DCIT]
Vinblastina lilly
vinblastine
Vinblastine
Vinblastine (INN)
Vinblastine [INN:BAN]
Vinblastine sulfate
Vinblastine Sulfate
Vinblastinsulfat-gry
Vinblastinum
Vinblastinum [INN-Latin]
Vincaleucoblastin
Vincaleucoblastine
Vincaleukoblastine
Vincoblastine
VLB
VR-8
|
|
| 31 |
|
Vindesine |
Approved, Investigational |
Phase 3 |
|
59917-39-4, 53643-48-4 |
40839
|
|
Synonyms:
3-(aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-(Aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-(Aminocarbonyl)-O(sup 4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
53643-48-4
AC1L24KY
C43H55N5O7
CHEBI:36373
CHEMBL219146
CID40839
Compound 112531
D06304
DAVA
DB00309
Desacetylvinblastine amide
Desacetylvinblastine amide sulfate
Desacetylvinblastine Amide Sulfate
EG labo brand OF vindesine sulfate
EINECS 258-682-2
Eldesine
Eldisine
Enison
|
HMS2090E15
HSDB 6961
Lilly 112531
Lilly brand OF vindesine sulfate
LS-162145
methyl (5S,7S,9S)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
MolPort-005-933-570
NSC-245467
STOCK1N-75293
Sulfate, vindesine
UNII-RSA8KO39WH
Vindesin
Vindesina
Vindesina [INN-Spanish]
vindesine
Vindesine (USAN/INN)
Vindesine [USAN:BAN:INN]
Vindesine [USAN:INN:BAN]
Vindesine sulfate
Vindesine Sulfate
Vindesinum
Vindesinum [INN-Latin]
|
|
| 32 |
|
Bevacizumab |
Approved, Investigational |
Phase 3,Phase 2,Phase 1 |
|
216974-75-3 |
|
|
Synonyms:
216974-75-3
antiVEGF
anti-VEGF monoclonal antibody
Avastin
Avastin (TN)
bevacizumab
|
Bevacizumab
Bevacizumab (genetical recombination)
Bevacizumab (genetical recombination) (JAN)
bevacizumab-awwb
D06409
R-435
|
|
| 33 |
|
Cetuximab |
Approved |
Phase 3,Phase 2,Phase 1 |
|
205923-56-4 |
56842117
2333
|
|
Synonyms:
205923-56-4
Anti EGFR
cetuximab
Cetuximab
Cétuximab
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
|
Cetuximab (USAN/INN)
Cetuximabum
D03455
Erbitux
Erbitux (TN)
IMC-C225
Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer
|
|
| 34 |
|
Lenograstim |
Approved, Investigational |
Phase 3,Phase 2 |
|
135968-09-1 |
|
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
|
|
| 35 |
|
Celecoxib |
Approved, Investigational |
Phase 3,Phase 2 |
|
169590-42-5 |
2662
|
|
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC1L1E6K
AC-4228
AI-525
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
celecoxib
Celecoxib
Célécoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
cMAP_000027
CPD000550473
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
|
KBio2_000912
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
Medicoxib
MLS001165684
MLS001195656
MLS001304708
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulphonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC58635
SC-58635
SMR000550473
Solexa
SPBio_001512
Spectrum_000432
SPECTRUM1503678
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM177
YM-177
ZINC02570895
|
|
| 36 |
|
nivolumab |
Approved |
Phase 3,Phase 2 |
|
946414-94-4 |
|
|
Synonyms:
|
| 37 |
|
Palbociclib |
Approved, Investigational |
Phase 2, Phase 3,Phase 3,Phase 1 |
|
571190-30-2 |
11431660
5005498
5330286
|
|
Synonyms:
2euf
571190-30-2
6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one
AC1NS8RV
CHEMBL189963
CID5330286
EC-000.2350
Ibrance
|
Kinome_3823
Kinome_3824
LQQ
Palbociclib
PD 0332991
PD 332991, PD 0332991, PD0332991
PD0332991
PD-0332991
PD-332991
S1116_Selleck
|
|
| 38 |
|
Ponatinib |
Approved, Investigational |
Phase 2, Phase 3 |
|
943319-70-8 |
24826799
|
|
Synonyms:
3-(2-(imidazo(1,2-b)Pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-y-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
AP 24534
AP24534
Iclusig
|
ponatinib
Ponatinib
Ponatinib hydrochloride
Ponatinibum
|
|
| 39 |
|
Cytarabine |
Approved, Investigational |
Phase 3 |
|
147-94-4 |
6253
|
|
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
147-94-4
1-Arabinofuranosylcytosine
1-b-D-Arabinofuranosylcytosine
1beta -Arabinofuranasylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1beta -D-Arabinofuranosylcytosine
1-beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosyl-cytosine
1-beta-D-Arabinofuranosylcytosine, cytosine arabinoside
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1beta-D-Arabinosylcytosine
1-beta-D-Arabinosylcytosine
1-beta-D-Arabinosyl-cytosine
1-β-D-arabinofuranosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-amino-1-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-amino-1-b-D-Arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-b-D-Arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-amino-1-beta-D-Arabinofuranosyl-2(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
4-amino-1-beta-D-Arabinofuranosylpyrimidin-2(1H)-one
4-amino-1-β-D-arabinofuranosyl-2(1H)-pyrimidinone
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
Alexan
AR3
Arabinocytidine
Arabinofuranosylcytosine
Arabinoside, cytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
AraC
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Aracytidine
Ara-Cytidine
Aracytin
Aracytine
Arafcyt
beta -Arabinosylcytosine
beta -Cytosine arabinoside
beta -D-Arabinosylcytosine
beta-Ara c
beta-Ara C
beta-Arabinosylcytosine
beta-Cytosine arabinoside
Beta-cytosine arabinoside
beta-D-Arabinosylcytosine
BIDD:GT0371
BIDD:PXR0139
BTB15125
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
Citarabina
|
Citarabina [INN-Spanish]
CPD000449317
Cytarabin
Cytarabina
cytarabine
Cytarabine (JP15/USP/INN)
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Cytarabine [USAN:INN:BAN:JAN]
Cytarabine hydrochloride
cytarabine liposome injection
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar u
Cytosar-u
CytosarU
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-b-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-1-β-D-arabinofuranoside
Cytosinearabinoside
Cytosine-b-D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta -D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosine-beta-D-arabinofuranoside
cytosine-β-D-arabinofuranoside
Cytosine-β-D-arabinofuranoside
D00168
DB00987
Depocyt
Depocyt (liposomal)
Depocyt (TN)
Depocyte
DepoCyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Hydrochloride, cytarabine
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
Lopac0_000316
LS-860
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
Spongocytidine
SR-01000075773-3
Tarabine
TL8001048
U 19920A
U-19,920
U-19920
Udicil
UNII-04079A1RDZ
ZINC03795098
|
|
| 40 |
|
Iniparib |
Investigational |
Phase 3 |
|
160003-66-7 |
|
|
Synonyms:
4-iodo-3-nitrobenzamide
BSI-201
|
|
|
| 41 |
|
Tirapazamine |
Investigational |
Phase 3,Phase 1 |
|
27314-97-2 |
|
|
Synonyms:
1,2,4-benzotriazin-3-amine, 1,4-dioxide
|
3-Amino-1,2,4-benzotriazine 1,4-dioxide
|
|
| 42 |
|
Talazoparib |
Investigational |
Phase 2, Phase 3 |
|
1207456-01-6 |
|
| 43 |
|
Tremelimumab |
Investigational |
Phase 2, Phase 3 |
|
745013-59-6 |
|
|
Synonyms:
|
| 44 |
|
Alkylating Agents |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
| 45 |
|
Antineoplastic Agents, Alkylating |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
| 46 |
|
Antirheumatic Agents |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
| 47 |
|
Etoposide phosphate |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
| 48 |
|
Topoisomerase Inhibitors |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
| 49 |
|
Angiogenesis Inhibitors |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
| 50 |
|
Angiogenesis Modulating Agents |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 220)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer |
Unknown status |
NCT02031601
|
Phase 4 |
Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib |
| 2 |
Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma |
Completed |
NCT02088515
|
Phase 4 |
Nedaplatin;Cisplatin;Docetaxel |
| 3 |
Lipusu Advanced Squamous Cell Carcinoma of Lung Study Carboplatin in Advanced Squamous Cell Carcinoma of Lung |
Not yet recruiting |
NCT02996214
|
Phase 4 |
Paclitaxel Liposome;Gemcitabine;Cisplatin |
| 4 |
Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer |
Unknown status |
NCT02643407
|
Phase 3 |
Docetaxel;Nedaplatin;Cisplatin |
| 5 |
Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma |
Unknown status |
NCT01947062
|
Phase 3 |
Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide |
| 6 |
The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration. |
Unknown status |
NCT02283476
|
Phase 3 |
Endostar continuous intravenous infusion;Endostar routine intravenous infusion;Gemcitabine;Cisplatin |
| 7 |
Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer |
Unknown status |
NCT00955695
|
Phase 3 |
erlotinib hydrochloride;gefitinib |
| 8 |
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) |
Completed |
NCT01082549
|
Phase 3 |
gemcitabine/carboplatin;gemcitabine/carboplatin plus Iniparib |
| 9 |
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy |
Completed |
NCT01523587
|
Phase 3 |
afatinib;erlotinib |
| 10 |
Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. |
Completed |
NCT01652469
|
Phase 3 |
Erlotinib;Docetaxel |
| 11 |
Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery |
Completed |
NCT00003387
|
Phase 3 |
carboplatin;chemotherapy;paclitaxel |
| 12 |
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed |
Completed |
NCT00003235
|
Phase 3 |
carboplatin;paclitaxel |
| 13 |
Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer |
Completed |
NCT00002550
|
Phase 3 |
cisplatin;etoposide |
| 14 |
Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery |
Completed |
NCT00020709
|
Phase 3 |
cisplatin;docetaxel;etoposide;gefitinib |
| 15 |
Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery |
Completed |
NCT00005838
|
Phase 3 |
shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel |
| 16 |
Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer |
Completed |
NCT00003831
|
Phase 3 |
|
| 17 |
Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer |
Completed |
NCT00002852
|
Phase 3 |
paclitaxel;carboplatin |
| 18 |
Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery |
Completed |
NCT00049543
|
Phase 3 |
gefitinib |
| 19 |
Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer |
Completed |
NCT00028938
|
Phase 3 |
carboplatin;paclitaxel |
| 20 |
Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer |
Completed |
NCT00002623
|
Phase 3 |
carboplatin;cisplatin |
| 21 |
Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer |
Completed |
NCT00006484
|
Phase 3 |
carboplatin;paclitaxel;tirapazamine |
| 22 |
Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery |
Completed |
NCT00003901
|
Phase 3 |
|
| 23 |
Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
NCT00079287
|
Phase 3 |
carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate |
| 24 |
Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer |
Completed |
NCT00003117
|
Phase 3 |
carboplatin;paclitaxel |
| 25 |
Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer |
Completed |
NCT00003685
|
Phase 3 |
|
| 26 |
Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer |
Completed |
NCT00002823
|
Phase 3 |
cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate |
| 27 |
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers |
Recruiting |
NCT02785952
|
Phase 3 |
|
| 28 |
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer |
Recruiting |
NCT02154490
|
Phase 2, Phase 3 |
Docetaxel;Erlotinib Hydrochloride;FGFR Inhibitor AZD4547;Palbociclib;Talazoparib;Taselisib |
| 29 |
A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC |
Recruiting |
NCT03150875
|
Phase 3 |
Docetaxel |
| 30 |
To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer |
Recruiting |
NCT02974426
|
Phase 3 |
Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen) |
| 31 |
Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC |
Recruiting |
NCT02455843
|
Phase 3 |
|
| 32 |
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) |
Recruiting |
NCT02194738
|
Phase 3 |
Crizotinib;Erlotinib Hydrochloride |
| 33 |
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers |
Active, not recruiting |
NCT02766335
|
Phase 2, Phase 3 |
Docetaxel |
| 34 |
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches |
Active, not recruiting |
NCT02926638
|
Phase 2, Phase 3 |
Erlotinib Hydrochloride |
| 35 |
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer |
Active, not recruiting |
NCT02785939
|
Phase 2, Phase 3 |
Docetaxel;Palbociclib |
| 36 |
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer |
Active, not recruiting |
NCT02965378
|
Phase 2, Phase 3 |
Docetaxel;FGFR Inhibitor AZD4547 |
| 37 |
Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients |
Active, not recruiting |
NCT00030771
|
Phase 3 |
Chemotherapy |
| 38 |
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer |
Active, not recruiting |
NCT00946712
|
Phase 3 |
Carboplatin;Paclitaxel |
| 39 |
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer |
Active, not recruiting |
NCT00499330
|
Phase 3 |
|
| 40 |
Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer |
Not yet recruiting |
NCT03262948
|
Phase 3 |
nab-paclitaxel;Paclitaxel;Carboplatin |
| 41 |
Photodynamic Therapy for the Prevention of Lung Cancer |
Not yet recruiting |
NCT03346304
|
Phase 2, Phase 3 |
|
| 42 |
Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly Patients With Advanced Non-small Cell Lung Cancer |
Not yet recruiting |
NCT03351361
|
Phase 3 |
Nivolumab + Ipilimumab;Chemotherapy |
| 43 |
Ponatinib for Squamous Cell Lung and Head and Neck Cancers |
Terminated |
NCT01761747
|
Phase 2, Phase 3 |
ponatinib |
| 44 |
Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer |
Terminated |
NCT00113386
|
Phase 3 |
cisplatin;docetaxel |
| 45 |
Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer |
Terminated |
NCT00004859
|
Phase 3 |
carboplatin;paclitaxel;thalidomide |
| 46 |
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer |
Terminated |
NCT01041781
|
Phase 3 |
carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium |
| 47 |
Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer |
Terminated |
NCT00863512
|
Phase 3 |
cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate |
| 48 |
Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer |
Withdrawn |
NCT00055887
|
Phase 3 |
carboplatin;cisplatin;efaproxiral;gemcitabine hydrochloride;paclitaxel;vinorelbine ditartrate |
| 49 |
Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer |
Withdrawn |
NCT00054392
|
Phase 3 |
carboplatin;gemcitabine hydrochloride;paclitaxel |
| 50 |
Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy |
Unknown status |
NCT01660399
|
Phase 2 |
Boanmycin;Docetaxel |
|
